Alleviating Inflammatory and Neuroinflammatory Diseases

NodThera is a Cambridge (UK) headquartered biotech engaged in innate immune/ inflammasome research. Our leading project is focused on developing inhibitors of the NLRP3 inflammasome for the treatment of inflammatory and neuroinflammatory diseases.

latest news
Oct 23, 2018
NodThera announces the appointment of Alison Strutt PhD as Head of Finance & Operations, the launch of its new corporate office in Boston and the opening of its laboratory in Seattle

Expansion in the US is consistent with NodThera’s strategy to access world class talent, foster collaborative relationships...

Sep 23, 2018
NodThera announces the appointment of Adam Keeney PhD as President and Chief Executive Officer

Dr Keeney joins NodThera with over 20 years of pharmaceutical industry experience, including most recently at Sanofi and...

Jun 25, 2018
NodThera secures £28 million ($40 million) Series A Financing
  • NodThera discovers and develops next generation NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic...
about us

NLRP3 inflammasome inhibitors represent a new generation of medicines for the treatment of many debilitating chronic conditions

NodThera is a biotechnology company focused on the discovery and development of new treatments for diseases driven by chronic inflammation. NodThera was seed funded by Epidarex Capital based on research from Selvita.

Inflammation is a protective immune response to noxious stimuli; however, improper activation of the innate immune system can lead to chronic inflammation and disease.

Inflammasomes are key components of the inflammatory response. These multi-protein complexes, when inappropriately activated, are implicated in a wide range of diseases including arthritis, atherosclerosis, Alzheimer’s disease, diabetes and certain cancers, the prevalence of which are all increasing dramatically. NodThera is initially targeting the NLRP3 inflammasome with small molecule inhibitors and is building a pipeline of NLRP3 inflammasome inhibitors through a highly differentiated, next generation approach that builds on and enhances existing understanding of NLRP3 biochemistry and its role in inflammation.

about us

NLRP3 inflammasome inhibitors represent a new generation of medicines for the treatment of many debilitating chronic conditions

NodThera is a biotechnology company focused on the discovery and development of new treatments for diseases driven by chronic inflammation. NodThera was seed funded by Epidarex Capital based on research from Selvita.

Inflammation is a protective immune response to noxious stimuli; however, improper activation of the innate immune system can lead to chronic inflammation and disease.

Inflammasomes are key components of the inflammatory response. These multi-protein complexes, when inappropriately activated, are implicated in a wide range of diseases including arthritis, atherosclerosis, Alzheimer’s disease, diabetes and certain cancers, the prevalence of which are all increasing dramatically. NodThera is initially targeting the NLRP3 inflammasome with small molecule inhibitors and is building a pipeline of NLRP3 inflammasome inhibitors through a highly differentiated, next generation approach that builds on and enhances existing understanding of NLRP3 biochemistry and its role in inflammation.

management team
senior team

Chris Gabel PhD

VP Biology

Mark Bock PhD

VP Medicinal Chemistry
board
investors
contact us
Cambridge

Suite 8, The Mansion
Chesterford Research Park
Little Chesterford
CB10 1XL, UK
Boston

430 Bedford Street
Lexington
Massachusetts 02420
USA
Seattle

454 N 34th Street
Seattle
WA 98103
USA
Telephone

+44 (0) 1223 608130
(main office)

Email
Media enquiries – nodthera@consilium-comms.com
Job enquiries – jobs@nodthera.com
Business enquiries – info@nodthera.com

Cambridge
Boston
Seattle
close bio
join us

Based in Cambridge UK and with offices in Seattle WA and Boston MA, NodThera is a global business.

As we push the frontiers of inflammation research we are looking to work with experts in the fields of immunology and drug discovery. If you’d like to work with us, we look forward to hearing from. Please email us at jobs@nodthera.com